Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)Article Published on 2022-09-212022-11-15 Journal: BMC Infectious Diseases [Category] SARS, 진단, 치료기술, [키워드] age analyzed anti-SARS-CoV-2 Anti-spike Antiretroviral therapy black BNT162b2 booster CD4 CD8 cells clinically COVID-19 COVID-19 vaccination COVID-19 vaccine decrease demographics detectable dose exploratory female HIV Humoral immunity IgG IgG levels immune response immunogenicity majority male marker median MOST occurred offered Older outcome participant positive presenting primary analysis protective immunity quantitative assessment reactogenicity recruited responses SARS-CoV-2 secondary single-center Spike protein subject suppressed T-cell T-cell Response vaccination Viremia virus-specific T-cell response white Wilcoxon signed-rank test with HIV [DOI] 10.1186/s12879-022-07737-0 PMC 바로가기
HLA alleles, disease severity, and age associate with T-cell responses following infection with SARS-CoV-2Article Published on 2022-09-062022-11-16 Journal: Communications Biology [Category] SARS, 치료기술, [키워드] age antibodies CD4 CD8 contributing to controls convalescent disease severity eight Factor functional heterogeneity HLA HLA alleles Humoral response Icelanders induce infection with SARS-CoV-2 investigated Protein reactive SARS-CoV-2 SARS-COV-2 infection Symptom T-cell immunity T-cell Response T-cell responses the N protein uninfected [DOI] 10.1038/s42003-022-03893-w PMC 바로가기
Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulationArticle Published on 2022-09-012022-11-15 Journal: Nanomedicine : nanotechnology, biology, and medici [Category] SARS, 진단, [키워드] Activation acute respiratory syndrome addition antibody Antigen C57BL/6 CD4 Complete conditions coronavirus COVID-19 demonstrated Diseases displaying dose effective hallmark highlight IgG immune response immunization in vitro in vivo Lipid-based nanoparticles mice modulated MPLA Nano-multilamellar vesicles promote Protein RBD Receptor binding domain reduced required responses Safe SARS-CoV-2 serum spike subunit Subunit vaccine T-cell Response T-cell responses toxic effect Vaccine Vaccines Vesicle virus-neutralizing antibody [DOI] 10.1016/j.nano.2022.102595 PMC 바로가기
Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucelArticle Published on 2022-09-012023-07-08 Journal: Pediatric hematology and oncology [Category] COVID19(2023년), [키워드] CD19 directed therapy chimeric antigen receptor SARS-CoV-2 T-cell Response tisagenlecleucel. [DOI] 10.1080/08880018.2022.2035864
Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile칠레의 면역 저하 환자 집단에서 비활성화된 중증 급성 호흡기 증후군 코로나바이러스 2 백신에 대한 면역 반응 감소Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody Autoimmune Cancer Cell clinical concentrations conducted control group controls CoronaVac coronavirus coronavirus 2 COVID-19 dose Enrollment evaluate groups HIV HIV group Human immunodeficiency virus humoral immune response Immunocompromised Immunocompromised patient immunocompromising condition Immunoglobulin Inactivated vaccine Infection interferon γ median Neutralizing activity not differ not significant participant patients prospective cohort study receiving Red reduce respiratory response rheumatic disease SARS-CoV-2 significantly solid organ transplant solid tumor T cell T-cell Response Trial Vaccination strategy Vaccine vulnerable patients [DOI] 10.1093/cid/ciac167 PMC 바로가기 [Article Type] Article
Long-Term Accuracy of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay and Its Application in Household Investigation중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 인터페론-γ 방출 분석의 장기 정확도 및 가정 조사에서의 적용Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody responses antigen-specific T cell application applied Blood Blood donors cell-mediated immune cell-mediated immune response clinical assessment collected Contact convalescent coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 declined detect diagnostic epidemiological Epidemiological investigation evaluated exhibiting healthy blood donors household Households IFN-γ IgG IGRA Immunocompromised Immunocompromised patients index case index cases interferon investigation lithium Lithium heparin mitogen peptide peptide pool positive Post-infection Release remained respiratory responses robust SARS-CoV-2 SARS-CoV-2 antigen sensitivity Sensitivity and specificity severe acute respiratory syndrome Coronavirus stimulated T cells T-cell T-cell Response tested Vaccines variant Whole blood whole blood assay [DOI] 10.1093/cid/ciac045 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in ChileArticle Published on 2022-08-242022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, [키워드] activate acute respiratory syndrome Adverse reaction age analyzed binding domain blood sample cellular characterized Chilean circulating clinical trial CoronaVac coronavirus coronavirus 2 coronavirus disease COVID-19 dose effective vaccine enrolled healthy humoral IFN-γ IgG immunogenicity Immunoglobulin inactivated incidence induce injection interferon-γ Local measure Mild neutralizing antibody neutralizing capacity Pain peptide Phase 3 phase 3 clinical trial Placebo pool profiles promote Randomly RBD Registered reported respiratory Safe Safety SARS-CoV-2 SARS-CoV-2 antigens second dose secretion separated severe adverse event significant increase subset T cells T-cell Response the vaccine Vaccine Vaccines Volunteer volunteers was performed [DOI] 10.1093/cid/ciab823 PMC 바로가기
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 특이적 T 세포 및 항체, 코로나바이러스 질병 2019(COVID-19) 보호: 전향적 연구Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus analyzed antibody Antibody Response Antibody responses CD4+ CD8+ T cell CD8+ T cells clinical comparable coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 correlated COVID-19 demonstrated ELISPOT enzyme enzyme-linked immunosorbent evaluated flow cytometry followed by fraction Fractions frequencies Frequency healthcare highest IFN-γ IgG immune immune response Immunoglobulin Immunoglobulin G immunoglobulin M individual Infection interferon gamma interleukin interleukin 2 Kaplan-Meier estimator membrane nucleocapsid pandemic positive Probability Prospective PROTECT protective effect question Registration respiratory response SARS-CoV-2 SARS-COV-2 infection Spike protein Spike proteins staining T cell T cells T-cell T-cell and antibody responses T-cell Response T-cell responses the SARS-CoV-2 virus virus-specific antibodies Virus-specific IgG were infected with infection [DOI] 10.1093/cid/ciac278 PMC 바로가기 [Article Type] Article
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination감염 또는 백신 접종 후 T-세포 반응의 간단한 검출을 위한 표준화된 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 인터페론-γ 방출 분석의 임상 성능Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, [키워드] 19 2 95% confidence interval Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 best Cell cell response Chain Reaction clinical convalescent Convalescent patients coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 CoV COVID COVID-19 dependent on detection disease severity Euroimmun evaluated Follow-up Germany healthy IFN-γ IFN-γ response IFN-γ responses IGRA immune response individual Infection interferon interferon-γ magnitude Mild disease mild infections Neutralizing antibodies neutralizing antibody Patient performance polymerase chain reaction positive Primary infection Prospective Study Quantitative reference standard Release respiratory response reverse transcription Reverse transcription-polymerase chain reaction SARS SARS-CoV-2 SARS-COV-2 infection sensitivity serological serological test Serological tests serology severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe COVID-19 severity severity of illness simple specificity subject subjects T T-cell T-cell Response uninfected vaccination was measured Whole blood with mild disease γ release assay. [DOI] 10.1093/cid/ciab1021 PMC 바로가기 [Article Type] Article
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort StudyCOVID-19 백신 접종 후 항-CD20 치료 환자의 강력한 T-세포 반응: 전향적 코호트 연구Observational Study Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus anti-CD20 anti-CD20 therapy anti-CD20 treatment antibodies antibody Antibody Response Arthritis Breakthrough infection CD20 CD4 CD4 T cell CD8 T cell CD8 T cells cohort study Complication Control controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine detectable dose Effectiveness effector molecule effector molecules expressed Follow-up had no humoral humoral responses individual Mild mRNA COVID-19 vaccines mRNA-based COVID-19 vaccine multiple sclerosis Ocrelizumab Patient patients treated Prospective prospective observational cohort reduction respiratory response response rate response rates rheumatic disease Rheumatic diseases rheumatoid arthritis risk rituximab seroconverted severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe coronavirus disease severe COVID-19 significantly lower specific antibodies spike T cell T cells T-cell T-cell Response T-cell responses Th1 phenotype treated treated patient vaccination [DOI] 10.1093/cid/ciab954 PMC 바로가기 [Article Type] Observational Study